Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746392 | 0.85 | RECQL (0.62) | SMN1; SMN2ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL800634 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749086 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749185 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749056 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749144 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749221 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749227 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8392706 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2USP2ALDH1A1CA12CA1 | |
| SCHEMBL8749184 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2USP2ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220340523-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-7635684-B2 | treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-100413878-C | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2008-08-27 | — | — | CN | disclosed |
| EP-1297022-B1 | NOVEL PHOTOINITIATORS | KIMBERLY CLARK CO (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1688597-A | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1297022-A1 | NOVEL PHOTOINITIATORS AND APPLICATIONS THEREFOR | Kimberly-Clark Worldwide, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6486227-B2 | FOR USE IN GENERATING A REACTIVE SPECIES POLYMERIZING POLYMERIZABLE MATERIALS, FOR CURING UNSATURATED OLIGOMER/MONOMER MIXTURE, AND LAMINATING USING PHOTOINITIATORS, FOR INKS, ADHESIVES | KIMBERLY-CLARK WORLDWIDE, INC. | 2002-11-26 | — | — | US | disclosed |
| US-20020099111-A1 | Novel photoinitiators and applications therefor | MIND FUSION, LLC | 2002-07-25 | — | — | US | disclosed |
| WO-2002000735-A1 | NOVEL PHOTOINITIATORS AND APPLICATIONS THEREFOR | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340523-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | SMN1; SMN2 3088/4885USP2 2296/4885ALDH1A1 1585/4885 |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | SMN1; SMN2 3088/4885USP2 2296/4885ALDH1A1 1585/4885 |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | UGGT1, GCKR, SLC5A1 | SMN1; SMN2 4382/4885USP2 4450/4885ALDH1A1 335/4885 |
| US-20020099111-A1 | Novel photoinitiators and applications therefor | ARL1, VCL, RAD54L | SMN1; SMN2 4781/4885USP2 3530/4885ALDH1A1 137/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | SMN1; SMN2 4382/4885USP2 4450/4885ALDH1A1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.